Stage III Esophageal Cancer Clinical Trial
Official title:
A Phase II Trial to Compare Efficacy and Safety of Definitive Radiochemotherapy VS Neoadjuvant Radiochemotherapy Plus Surgery in Patients Who Achieved Clinical Complete Response After Neoadjuvant Treatment for Stage II-III Esophageal Cancer
Neoadjuvant chemoradiotherapy(Neo-CRT) plus surgery has been regarded as a standard of care for patients with resectable locally advanced oesophageal cancer. Many studies suggest that definitive Radiochemotherapy(CRT) has similar efficacy as neoadjuvant chemoradiotherapy plus surgery for esophageal cancers who respond to chemoradiation. Herein, a single center prospective randomized phase II clinical trial will be carried out to compare efficacy and safety of definitive radiochemotherapy versus neoadjuvant radiochemotherapy plus radical resection in patients who achieved clinical complete response(CCR) after neoadjuvant radiochemotherapy for stage II-III esophageal Cancer.
1. Compare progression-free survival (PFS) and overall survival (OS) of definitive
radiochemotherapy versus(VS) neoadjuvant radiochemotherapy plus radical resection for
esophageal cancer patients who achieved clinical complete response after neoadjuvant
treatment;
2. Compare the toxic and side effects of definitive radiochemotherapy versus neoadjuvant
radiochemotherapy plus radical resection for esophageal cancer patients who achieved
clinical complete remission after neoadjuvant treatment;
3. Compare the relationship and consistency between pathological complete response of
endoscopic biopsy specimens after neoadjuvant treatment and pathological complete
response of surgical specimens in neoadjuvant radiochemotherapy plus radical resection
group;
4. Assess impact of definitive radiochemotherapy versus neoadjuvant radiochemotherapy plus
radical resection on quality of life of patients.
Clinical Complete Response After Neoadjuvant Treatment: Endoscope biopsy pathologic diagnosis
indicate pathologic complete response after Neoadjuvant treatment; upper
gastrointestinal/chest CT and symptom assessment indicate clinical complete response after
Neoadjuvant treatment (Concurrent Radiochemotherapy: Radiotherapy, Intensity Modulation
Radiation Therapy(IMRT), 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2),
1st/8th/15th/22nd day
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00064259 -
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT00061958 -
Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction
|
Phase 2 | |
| Completed |
NCT00045526 -
Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05856500 -
A Study of Creatine Combined With Curcumin in the Intervention of Early Cachexia in Upper Gastrointestinal Tumors
|
N/A | |
| Completed |
NCT00607594 -
Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer
|
Phase 2 | |
| Completed |
NCT00030498 -
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
|
Phase 1 | |
| Not yet recruiting |
NCT03708042 -
A Study to Compare Efficacy and Safety of DRT VS CRT Plus Surgery in Patients Who Achieved CCR for Esophageal Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT03154190 -
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
|
N/A | |
| Completed |
NCT00004074 -
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
|
Phase 1 | |
| Completed |
NCT01561014 -
Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
|
Phase 1 |